These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36322272)

  • 1. ASO Author Reflections: Low Genetic Testing Utilization Among Patients with Breast, Ovarian, Pancreatic, and Prostate Cancers.
    Clark NM; Flanagan MR
    Ann Surg Oncol; 2023 Mar; 30(3):1327-1328. PubMed ID: 36322272
    [No Abstract]   [Full Text] [Related]  

  • 2. The Role of
    Pilarski R
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():79-86. PubMed ID: 31099688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    Minoura Y; Takahashi M; Maeda H; Kuwahara S; Tachikawa H; Yamamoto M; Tomioka N; Watanabe K; Sakurai A
    Breast Cancer; 2022 Sep; 29(5):808-813. PubMed ID: 35641852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASO Author Reflections: Reconsidering Resection for Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma.
    Kaslow SR; Correa-Gallego C
    Ann Surg Oncol; 2022 Jun; 29(6):3532-3533. PubMed ID: 35220501
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Progression after Resection of Noninvasive or Microinvasive Intraductal Papillary Mucinous Neoplasms.
    Al Efishat M; Allen PJ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):822-823. PubMed ID: 30324467
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Natural Language Processing Aids in the Detection of Incidental Pancreatic Lesions in Cross-Sectional Imaging.
    Kooragayala K; Lou J; Hong YK
    Ann Surg Oncol; 2022 Dec; 29(13):8520-8521. PubMed ID: 35969301
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
    Clark NM; Roberts EA; Fedorenko C; Sun Q; Dubard-Gault M; Handford C; Yung R; Cheng HH; Sham JG; Norquist BM; Flanagan MR
    Ann Surg Oncol; 2023 Mar; 30(3):1312-1326. PubMed ID: 36335273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASO Author Reflections: Pancreatic Resection Margins-Chasing Moons.
    Shah MM; Datta J; Merchant NB; Kooby DA
    Ann Surg Oncol; 2022 Mar; 29(3):1551-1552. PubMed ID: 34997421
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
    Lorenzo Bermejo J; Hemminki K
    Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma.
    Tamburrino D; Guarneri G; Capurso G; Falconi M
    Ann Surg Oncol; 2021 Apr; 28(4):2323-2324. PubMed ID: 32929602
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Frailty in Pancreatic Cancers.
    Zhang F; Yan Y; Ge C
    Ann Surg Oncol; 2024 Jan; 31(1):545. PubMed ID: 37843665
    [No Abstract]   [Full Text] [Related]  

  • 12. ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma.
    Ono M; Nakamura T; Mizukami Y; Hirano S
    Ann Surg Oncol; 2022 Aug; 29(8):5020-5021. PubMed ID: 35527329
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Dec; 25(13):3994-3995. PubMed ID: 30315385
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma.
    Jin W; Xu HX; Yu XJ; Liu L
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):571-572. PubMed ID: 30710182
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Exploring the Oncologic Impact of Pancreatic Fistula after Distal Pancreatectomy for Ductal Adenocarcinoma.
    Leon P; Panaro F
    Ann Surg Oncol; 2021 Jun; 28(6):3184-3185. PubMed ID: 33221981
    [No Abstract]   [Full Text] [Related]  

  • 16. ASO Author Reflections: Health Disparities in Pancreatic Cancer.
    Lutfi W; Hogg ME
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):824-825. PubMed ID: 30377920
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Re-Excision for Ductal Carcinoma In Situ: Who Is at Risk?
    Lamb LR; Bahl M
    Ann Surg Oncol; 2021 Mar; 28(3):1398-1399. PubMed ID: 32946015
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: Role of SOX9 Transcription Factor in Pancreatic Neoplasms.
    Turner K; Gnerlich JL
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):567-568. PubMed ID: 30680476
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma.
    Kubota K; Shimizu A; Soejima Y
    Ann Surg Oncol; 2022 Feb; 29(2):1449-1450. PubMed ID: 34618246
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
    Groot VP; Wolfgang CL; He J
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.